Literature DB >> 2470760

RNA sequence analysis of a perinatal lethal osteogenesis imperfecta mutation.

E Patterson1, E Smiley, J Bonadio.   

Abstract

The perinatal lethal form of osteogenesis imperfecta often results from mutations which disrupt stable assembly, delay secretion, and cause excessive posttranslational modification of type I procollagen molecules. One such mutation was efficiently characterized by an indirect method of RNA sequence analysis. The mutation initially was localized in procollagen by mapping the distribution of abnormal posttranslational modification within the triple helical domain of mutant molecules. Total RNA was isolated from osteogenesis imperfecta cells in culture, cDNA was synthesized using alpha 1(I) and alpha 2(I) specific primers, and fragments of cDNA suspected to harbor the mutation were amplified by the polymerase chain reaction technique and then cloned in M13 vectors. Sequence analysis of the amplified cDNA revealed a new, heterozygous Gly----Val substitution at residue 256 of the triple helical domain of alpha 1(I) chains produced by the perinatal lethal osteogenesis imperfecta cells. The nature and location of the mutation were confirmed by sequence analysis of amplified genomic DNA. A Gly----Val substitution has not previously been associated with the lethal form of osteogenesis imperfecta, and this mutation has the most amino-terminal location within the alpha 1(I) chain triple helical domain reported to date.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470760

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  A dominant mutation in the COL1A1 gene that substitutes glycine for valine causes recurrent lethal osteogenesis imperfecta.

Authors:  J Bonaventure; L Cohen-Solal; C Lasselin; P Maroteaux
Journal:  Hum Genet       Date:  1992-08       Impact factor: 4.132

Review 2.  Osteogenesis imperfecta: translation of mutation to phenotype.

Authors:  P H Byers; G A Wallis; M C Willing
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

3.  Disrupted growth plates and progressive deformities in osteogenesis imperfecta as a result of the substitution of glycine 585 by valine in the alpha 2 (I) chain of type I collagen.

Authors:  W G Cole; D Chan; C W Chow; J G Rogers; J F Bateman
Journal:  J Med Genet       Date:  1996-11       Impact factor: 6.318

4.  SSCP detection of a Gly565Val substitution in the pro alpha 1(I) collagen chain resulting in osteogenesis imperfecta type II.

Authors:  K Mackay; A M Lund; M Raghunath; B Steinmann; R Dalgleish
Journal:  Hum Genet       Date:  1993-06       Impact factor: 4.132

5.  Characterization of a type I collagen alpha 2(I) glycine-586 to valine substitution in osteogenesis imperfecta type IV. Detection of the mutation and prenatal diagnosis by a chemical cleavage method.

Authors:  J F Bateman; M Hannagan; D Chan; W G Cole
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

6.  The clinicopathological features of three babies with osteogenesis imperfecta resulting from the substitution of glycine by valine in the pro alpha 1 (I) chain of type I procollagen.

Authors:  W G Cole; E Patterson; J Bonadio; P E Campbell; D W Fortune
Journal:  J Med Genet       Date:  1992-02       Impact factor: 6.318

7.  Substitution of cysteine for glycine at residue 415 of one allele of the alpha 1(I) chain of type I procollagen in type III/IV osteogenesis imperfecta.

Authors:  A C Nicholls; J Oliver; D V Renouf; M Keston; F M Pope
Journal:  J Med Genet       Date:  1991-11       Impact factor: 6.318

8.  A Gly238Ser substitution in the alpha 2 chain of type I collagen results in osteogenesis imperfecta type III.

Authors:  N J Rose; K Mackay; P H Byers; R Dalgleish
Journal:  Hum Genet       Date:  1995-02       Impact factor: 4.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.